MX2016004441A - Tratamiento del cancer con una combinacion de plinabulina y taxano. - Google Patents
Tratamiento del cancer con una combinacion de plinabulina y taxano.Info
- Publication number
- MX2016004441A MX2016004441A MX2016004441A MX2016004441A MX2016004441A MX 2016004441 A MX2016004441 A MX 2016004441A MX 2016004441 A MX2016004441 A MX 2016004441A MX 2016004441 A MX2016004441 A MX 2016004441A MX 2016004441 A MX2016004441 A MX 2016004441A
- Authority
- MX
- Mexico
- Prior art keywords
- plinabulin
- combination
- taxane compound
- taxane
- cancer treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 229940123237 Taxane Drugs 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 4
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 title abstract 4
- 229950011498 plinabulin Drugs 0.000 title abstract 4
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title 1
- -1 taxane compound Chemical class 0.000 abstract 4
- 230000003247 decreasing effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 108010054981 dehydrophenylahistin Proteins 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000004235 neutropenia Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta invención proporciona un método de tratamiento del cáncer novedoso en el cual la plinabulina (t-butil-deshidrofenilhistina o NPI-2358) y un compuesto de taxano (como el docetaxel) son usados en combinación. Nuestro estudio ha mostrado que la combinación óptima de inyección de plinabulina después del compuesto de taxano tiene eficacia mejorada inesperada en poblaciones de tumores grandes en modelos con animales y en pacientes con cáncer NSCLC en comparación con el tratamiento con compuesto de taxano solo. Además, esta combinación óptima puede alcanzar un efecto inesperadamente seguro en la disminución de los efectos laterales insoportables, incluyendo la disminución en sus tasas neutropenias en todos los grados y disminución del uso de G-CFS en pacientes con cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2013/085075 WO2015051543A1 (en) | 2013-10-11 | 2013-10-11 | Cancer treatment with combination of plinabulin and taxane |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016004441A true MX2016004441A (es) | 2016-10-28 |
Family
ID=52812462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004441A MX2016004441A (es) | 2013-10-11 | 2013-10-11 | Tratamiento del cancer con una combinacion de plinabulina y taxano. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10596169B2 (es) |
| EP (1) | EP3076972B1 (es) |
| JP (1) | JP6411523B2 (es) |
| KR (1) | KR102225371B1 (es) |
| CN (1) | CN105705148B (es) |
| AU (1) | AU2013402794B2 (es) |
| BR (1) | BR112016007946A2 (es) |
| CA (1) | CA2926771C (es) |
| DK (1) | DK3076972T3 (es) |
| ES (1) | ES2902665T3 (es) |
| IL (1) | IL244984B (es) |
| MX (1) | MX2016004441A (es) |
| MY (1) | MY185650A (es) |
| NZ (1) | NZ719049A (es) |
| RU (1) | RU2662298C2 (es) |
| SG (1) | SG11201602637QA (es) |
| WO (1) | WO2015051543A1 (es) |
| ZA (1) | ZA201602380B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY193968A (en) * | 2015-02-12 | 2022-11-03 | Beyondspring Pharmaceuticals Inc | Use of plinabulin in combination with immune checkpoint inhibitors |
| MX2017011375A (es) * | 2015-03-06 | 2018-01-23 | Beyondspring Pharmaceuticals Inc | Método para tratar un tumor cerebral. |
| KR102626155B1 (ko) | 2015-03-06 | 2024-01-17 | 비욘드스프링 파마수티컬스, 인코포레이티드. | Ras 돌연변이와 관련된 암의 치료 방법 |
| EP4011878A1 (en) | 2015-07-13 | 2022-06-15 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| CA3013467A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| KR20230018545A (ko) * | 2016-06-06 | 2023-02-07 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증을 줄이는 조성물 및 방법 |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| KR20190109479A (ko) * | 2017-02-01 | 2019-09-25 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증의 감소 방법 |
| CN110603037A (zh) * | 2017-03-13 | 2019-12-20 | 大连万春布林医药有限公司 | 普那布林的组合物及其用途 |
| CN109498627B (zh) * | 2017-09-15 | 2021-06-04 | 深圳华大海洋科技有限公司 | 一种治疗肿瘤的药物组合物及其应用 |
| JP7350015B2 (ja) * | 2018-01-24 | 2023-09-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | プリナブリンの投与による血小板減少症を軽減するための組成物および方法 |
| JP2021512121A (ja) * | 2018-02-01 | 2021-05-13 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | プリナブリンおよびｇ−ｃｓｆ製剤の投与による化学療法誘発性好中球減少症を軽減するための組成物および方法 |
| CN108524442B (zh) * | 2018-06-05 | 2022-01-28 | 深圳海王医药科技研究院有限公司 | 一种抗肿瘤药物的注射剂及其制备方法 |
| JP2018199726A (ja) * | 2018-09-26 | 2018-12-20 | ビヨンドスプリング インコーポレイテッド | プリナブリン及びタキサンの組合せがん治療 |
| MX2021005646A (es) * | 2018-11-14 | 2021-08-11 | Beyondspring Pharmaceuticals Inc | Métodos de tratamiento de cáncer con agentes de unión a tubulina. |
| CN110507653B (zh) * | 2019-08-02 | 2022-12-02 | 北京赛而生物药业有限公司 | 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用 |
| EP4045046A4 (en) * | 2019-10-15 | 2024-01-10 | Beyondspring Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATING IRON DISEASES |
| EP4319751A1 (en) * | 2021-04-09 | 2024-02-14 | Beyondspring Pharmaceuticals, Inc. | Therapeutic compositions and methods for treating tumors |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN117860672A (zh) * | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| CN100540548C (zh) | 2002-08-02 | 2009-09-16 | 尼瑞斯药品公司 | 脱氢苯基阿夕斯丁及其类似物以及脱氢苯基阿夕斯丁及其类似物的合成 |
| NZ548659A (en) | 2004-02-04 | 2011-01-28 | Nereus Pharmaceuticals Inc | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| CA2905418C (en) | 2013-03-13 | 2023-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
-
2013
- 2013-10-11 MY MYPI2016000620A patent/MY185650A/en unknown
- 2013-10-11 JP JP2016547208A patent/JP6411523B2/ja active Active
- 2013-10-11 MX MX2016004441A patent/MX2016004441A/es unknown
- 2013-10-11 WO PCT/CN2013/085075 patent/WO2015051543A1/en active Application Filing
- 2013-10-11 SG SG11201602637QA patent/SG11201602637QA/en unknown
- 2013-10-11 DK DK13895342.7T patent/DK3076972T3/da active
- 2013-10-11 NZ NZ719049A patent/NZ719049A/en unknown
- 2013-10-11 US US15/028,376 patent/US10596169B2/en active Active
- 2013-10-11 RU RU2016112608A patent/RU2662298C2/ru active
- 2013-10-11 KR KR1020167012255A patent/KR102225371B1/ko active IP Right Grant
- 2013-10-11 BR BR112016007946A patent/BR112016007946A2/pt not_active Application Discontinuation
- 2013-10-11 EP EP13895342.7A patent/EP3076972B1/en active Active
- 2013-10-11 CA CA2926771A patent/CA2926771C/en active Active
- 2013-10-11 ES ES13895342T patent/ES2902665T3/es active Active
- 2013-10-11 CN CN201380080185.5A patent/CN105705148B/zh active Active
- 2013-10-11 AU AU2013402794A patent/AU2013402794B2/en active Active
-
2016
- 2016-04-07 IL IL244984A patent/IL244984B/en unknown
- 2016-04-08 ZA ZA2016/02380A patent/ZA201602380B/en unknown
-
2020
- 2020-03-17 US US16/821,348 patent/US20200281921A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2926771A1 (en) | 2015-04-16 |
| EP3076972B1 (en) | 2021-10-06 |
| KR20160078987A (ko) | 2016-07-05 |
| RU2016112608A (ru) | 2017-11-16 |
| IL244984B (en) | 2022-05-01 |
| EP3076972A1 (en) | 2016-10-12 |
| AU2013402794A1 (en) | 2016-05-12 |
| JP2016536352A (ja) | 2016-11-24 |
| WO2015051543A8 (en) | 2016-04-21 |
| EP3076972A4 (en) | 2017-12-20 |
| KR102225371B1 (ko) | 2021-03-10 |
| SG11201602637QA (en) | 2016-05-30 |
| US20160250209A1 (en) | 2016-09-01 |
| AU2013402794B2 (en) | 2020-02-27 |
| WO2015051543A1 (en) | 2015-04-16 |
| CN105705148A (zh) | 2016-06-22 |
| NZ719049A (en) | 2020-06-26 |
| ZA201602380B (en) | 2022-05-25 |
| BR112016007946A2 (pt) | 2017-09-12 |
| IL244984A0 (en) | 2016-05-31 |
| US20200281921A1 (en) | 2020-09-10 |
| JP6411523B2 (ja) | 2018-10-24 |
| CA2926771C (en) | 2022-07-05 |
| US10596169B2 (en) | 2020-03-24 |
| CN105705148B (zh) | 2021-03-23 |
| ES2902665T3 (es) | 2022-03-29 |
| DK3076972T3 (da) | 2022-01-03 |
| MY185650A (en) | 2021-05-27 |
| RU2662298C2 (ru) | 2018-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016004441A (es) | Tratamiento del cancer con una combinacion de plinabulina y taxano. | |
| PH12016502066A1 (en) | Methods of treating bladder cancer | |
| MX2017007321A (es) | Terapias de combinacion. | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| NZ630367A (en) | Methods of treatment of pediatric solid tumor | |
| PH12017550063A1 (en) | Combination therapies for treating cancers | |
| WO2013177187A3 (en) | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| MX2015010312A (es) | Metodos para tratamiento del melanoma. | |
| MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| MX2019009437A (es) | Tratamiento de mielosupresion. | |
| MX2015006478A (es) | Inhibidores de glutaminasa y metodos de empleo. | |
| MX2016000131A (es) | Nanoparticulas polimericas de docetaxel para el tratamiento de cancer. | |
| MX2015014599A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer. | |
| MX2017015532A (es) | Terapia de combinacion pac-1. | |
| MX2023007706A (es) | Nanoparticulas para su uso como vacuna terapeutica. | |
| MX2015009277A (es) | Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| NZ707636A (en) | Ingenol-derived compounds that can be used for treating cancer | |
| MX2016005614A (es) | Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos. | |
| PH12016501101A1 (en) | Veliparib in combination with carboplatin for the treatment of triple negative breast cancer | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
| MX2016002307A (es) | Tratamiento para el cancer. | |
| MX2021001081A (es) | Terapia de combinacion para el tratamiento del cancer. |